Janice Lu

Aug 24, 2024 | cancernetwork.com | Joyce O’Shaughnessy |Janice Lu

BackgroundElacestrant the first oral selective estrogen receptor degrader (SERD) approved in estrogen receptor–positive ER+/HER2-negative (HER2–) advanced metastatic breast cancer that targets ESR1-mutated tumors.

Dec 28, 2023 | cancernetwork.com | Janice Lu |Rina Lokaj

Data from the phase 3 EMERALD trial (NCT03778931) indicated that elacestrant (Orserdu) appeared to yield significant PFS benefit vs standard-of-care endocrine therapy in estrogen receptor–positive/HER2-negative metastatic breast cancer, specifically in patients with ESR1–mutant breast cancer, according to Janice Lu, MD, PhD.1 In an interview with CancerNetwork® at the 2023 San Antonio Breast Cancer Symposium (SABCS), Lu, a professor and director of Breast Medical Oncology at Northwestern...

Dec 27, 2023 | cancernetwork.com | Janice Lu |Rina Lokaj

Positive findings from the phase 3 EMERALD trial (NCT03778931), assessing elacestrant (Orserdu) in estrogen receptor–positive, HER2-negative metastatic breast cancer, highlight the importance of checking ESR1 mutation expression before, during, and after treatment, according to Janice Lu, MD, PhD.1 In a conversation with CancerNetwork® during the 2023 San Antonio Breast Cancer Symposium (SABCS), Lu, professor and director of Breast Medical Oncology at Northwestern University Lurie...

Dec 22, 2023 | cancernetwork.com | Rina Lokaj |Janice Lu

Data from the phase 3 EMERALD trial (NCT03778931) indicated that elacestrant (Orserdu) appeared to yield significant PFS benefit vs standard-of-care endocrine therapy in ER-positive/HER2-negative metastatic breast cancer, and warrants further investigation, according to Janice Lu, MD, PhD at the 2023 San Antonio Breast Cancer Symposium (SABCS).1 In a conversation with CancerNetwork®, Lu, professor and director of Breast Medical Oncology at Northwestern University Lurie Comprehensive Cancer...

Dec 22, 2023 | obroncology.com | Janice Lu

Janice Lu, MD, PhD: Hi, I'm Dr. Janice Lu, director of breast medical oncology at Northwestern University, Lurie Comprehensive Cancer Center. I'm here with OBR today to discuss three abstracts presented at the 2023 San Antonio Breast Cancer Symposium. These abstracts focus on biomarker studies aiming to identify the most suitable matches using precision medicine, in particular in patients with ESR1 mutations, or PIK3CA, PTEN, and AKT alterations.